

1 Homeostatic inflammation in the placenta is protective against adult
2 cardiovascular and depressive outcomes

3

4 Eamon Fitzgerald* ^{1,2,3}, Mo Jun Shen ⁴, Hannah Ee Juen Yong ⁴, Zihan Wang ³, Irina Pokhvisneva ³,
5 Sachin Patel ³, Nicholas O'Toole ^{1,2,3}, Shiao-Yng Chan ^{4,5}, Yap Seng Chong ^{4,5}, Helen Chen ^{6,7}, Peter D
6 Gluckman ^{4,8}, Jerry Chan ^{6,7}, Patrick Kia Ming Lee ⁹, Michael J Meaney* ^{1,3,4,5,9}

7

8 1 Sackler Program for Epigenetics and Psychobiology, McGill University, Canada.

9 2 Ludmer Centre for Neuroinformatics and Mental Health, McGill University, Canada.

10 3 Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Canada.

11 4 Singapore Institute for Clinical Sciences, Agency for Science, Technology & Research, Singapore.

12 5 Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

13 6 KK Women's and Children's Hospital, Singapore.

14 7 Duke-National University of Singapore, Singapore.

15 8 The University of Auckland, Auckland, New Zealand.

16 9 Brain – Body Initiative, Agency for Science, Technology & Research, Singapore.

17

18

19 *Correspondence to: Dr Eamon Fitzgerald (eamon.fitzgerald@mcgill.ca) or Dr Michael J. Meaney
20 (michael.meaney@mcgill.ca)

21

22 Douglas Mental Health University Institute

23 Department of Psychiatry,

24 McGill University,

25 6875 Boul. LaSalle,

26 Montréal, Quebec, Canada H4H 1R3.

27 Tel: 514-761-6131

28

29

30 **Keywords:** Placenta, inflammation, depression, cardiovascular disorders, Hofbauer cells, genetics

31 **Abstract**

32 Pathological placental inflammation increases the risk for several adult disorders, but these
33 mediators are also expressed under homeostatic conditions, where their contribution to adult health
34 outcomes is unknown. Here we define an expression signature of homeostatic inflammation in the
35 term placenta and use expression quantitative trait loci (eQTLs) to create a polygenic score (PGS)
36 predictive of its expression. Using this PGS in the UK Biobank we carried out a phenome-wide
37 association study, followed by mendelian randomization and identified protective, sex-dependent
38 effects of the placental module on cardiovascular and depressive outcomes. Genes differentially
39 regulated by intra-amniotic infection and preterm birth were also over-represented within the
40 module. Our data support a model where disruption of placental homeostatic inflammation,
41 following preterm birth or intra-amniotic infection, contributes to the increased risk of depression
42 and cardiovascular disease observed in these individuals. Finally, we identify aspirin as a putative
43 modulator of this homeostatic inflammatory signature.

44

45

46

47 Introduction

48 Early studies, foundational to the developmental origins of health and disease (DOHaD) hypothesis,
49 described an increased risk of both cardiovascular disease and depression in those born at low birth
50 weight¹⁻⁵. As the site of maternal-fetal interface during pregnancy, the placenta is a critical regulator
51 of cardiovascular effects as well as those of mental health^{6,7}. For instance, monozygotic twins that
52 share a placenta are up to 6-fold more likely to be concordant for schizophrenia than monozygotic
53 twins with separate placentae⁸. Genetic studies have further reinforced the essential role of the
54 placenta in shaping adult health outcomes⁹⁻¹², with the role of placental inflammation being
55 particularly compelling¹³⁻¹⁶.

56 A large body of literature in model systems supports a causal role for prenatal infection in driving
57 adverse adult behavioural outcomes (reviewed by Estes and McAllister, 2016; Han *et al.*, 2021), but
58 the inflammatory mediators involved in the placental response to infection are also highly expressed
59 under healthy conditions^{19,20}. Work in the developing brain with microglia illustrates the important
60 homeostatic role of inflammatory mediators, which traditionally were thought to subserve functions
61 solely related to infection²¹. For instance, microglia are yolk sac derived macrophages and the
62 placenta is home to its own yolk sac-derived macrophage, Hofbauer cells. Like microglia these cells
63 have important homeostatic roles^{22,23}, but also display a robust response to infection^{22,24-26}. Little
64 has been done to identify the role of these cells or gene expression patterns related to placental
65 homeostatic inflammation. This is surprising as understanding homeostatic functions would also
66 likely be informative for disease mechanisms.

67 In this study, we hypothesized homeostatic patterns of placental inflammation would shape adult
68 health outcomes in offspring. To test this hypothesis, we performed a series of experiments using
69 the Singapore-based, Growing Up in Singapore Towards healthy Outcomes (GUSTO) and UK Biobank
70 cohorts. We first used RNA sequencing from 42 placental villous samples, obtained as part of the
71 GUSTO study, and used weighted correlation network analysis (WGCNA²⁷) to identify a gene co-
72 expression module associated with homeostatic inflammation. We discovered a module highly
73 enriched in Hofbauer cells. We leveraged previously identified placental expression quantitative trait
74 loci (eQTLs)²⁸ to generate a polygenic score (PGS; henceforth referred to as fetoplacental PGS),
75 which specifically predicted expression of the genes comprising this module. To explore the
76 functional relevance of this PGS we conducted a phenome-wide association study (pheWAS) in the
77 UK Biobank and identified significant associations (false discovery rate; FDR<0.05) with 21 traits
78 primarily within the cardiometabolic and mental health domains. We then used logistic regression
79 and Mendelian randomization analyses to demonstrate protective sex-dependent effects on
80 cardiovascular disease and depression related outcomes. Next, we demonstrated that our placental
81 module was highly enriched for genes differentially regulated by intra-amniotic infection and
82 preterm birth, and that these genes were among the most highly connected within the network.
83 These data support a model by which loss or disruption of Hofbauer function as a consequence of
84 preterm birth or intra-amniotic infection, respectively, contributes to the increased risk of
85 depression and cardiovascular disease observed in these individuals²⁹⁻³³. Finally using the Drug-
86 Gene Interaction database (DGIdb), we identify aspirin as a promising candidate that may have
87 therapeutic value when used prophylactically in populations at high risk of intra-uterine infection.

88

89

90 **Methods**

91 *Cohorts*

92 We used data from two population-based cohorts. The first was the Growing Up in Singapore
93 Towards healthy Outcomes (GUSTO; Soh *et al.*, 2014) cohort, a Singapore-based longitudinal birth
94 cohort that recruited mothers at least 18-years of age from the two largest maternity units in
95 Singapore. Ethical approval for GUSTO was granted by the relevant institutional boards (DSRB
96 reference D/09/021 and CIRB reference 2009/280/D) and written informed consent was received
97 from all participating mothers. The second data source was the UK Biobank, a large adult population-
98 based study in the UK. The UK Biobank is guided by an ethics advisory committee and informed
99 consent was received from all participants. Approval for the UK Biobank was obtained by the
100 Northwest Multicentre Research Ethics Committee (REC reference 11/NW/0382), the National
101 Information Governance Board for Health and Social Care and the Community Health Index Advisory
102 Group. Access to data used in the current study was obtained under application #41975. In all
103 analyses performed, sex was defined genetically. Samples sizes for specific analyses are described in
104 the relevant results or supplementary tables.

105 *Placental sampling*

106 Placenta samples (n=44; 2 subsequently excluded with hierarchical clustering) used in this study
107 were derived from term births with tissue collected within 40 minutes of delivery. Exclusion criteria
108 included antenatal smoking (confirmed with plasma cotinine Ng *et al.*, 2019), maternal BMI greater
109 than 30kg/m², antenatal fasting glucose greater than 7 mmol/L or 2 hour oral glucose tolerance test
110 result greater than 11.1 mmol/L, hypertensive disorders of pregnancy, birth prior to 37 weeks of
111 gestation and a gestational age and sex-standardized birthweight percentile less than 10%. Placental
112 biopsies were taken at random from 3 sites at the maternal-facing side, before removal of the
113 maternal decidua to primarily retain the placental villous tissue for analysis. Sampling sites were
114 then pooled and stored at -80C until further processing.

115 *RNA extraction and sequencing*

116 Total RNA was extracted from samples using the phenol-chloroform method, followed by large RNA
117 purification using the NucleoSpin miRNA kit (Machery-Nagel, Düren, Germany) as per
118 manufacturer's instructions. RNA concentrations were determined using a Nanodrop
119 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and RNA integrity number (RIN)
120 was measured using the Agilent 4200 TapeStation System (Santa Clara, CA, USA). Sequencing
121 libraries were prepared from samples with a RIN > 6 at Novogene AIT Genomics (Singapore). In brief,
122 ribosomal RNA was depleted with the Illumina Ribo-Zero Magnetic Kit for Human/Mouse/Rat (San
123 Diego, CA, USA). Library preparation was done using the NEB Next Ultra Directional RNA Library Prep
124 Kit (New England Biolabs, Ipswich, MA, USA), before sequencing was carried out using the Illumina
125 HiSeq platform with a minimum depth of 50 million paired-end 150bp reads. Sequencing quality was
126 assessed using FastQC³⁵ and MultiQC³⁶. Reads were aligned to the human hg19 genome and gene
127 level counts assembled with STAR Aligner³⁷. Samples had an average unique mapping rate of 93.5%.

128 *WGCNA*

129 First raw gene counts were converted to RPKM (Reads Per Kilobase of transcript per Million mapped
130 reads). Genes with missing information from more than 10% of samples were excluded.
131 Agglomerative Hierarchical Clustering and Euclidean distance were used to assess outliers. After
132 which 42 samples and a total of 31,097 genes remained. Gene co-expression networks were

133 constructed by automatic block-wise network construction and the module detection process
134 implemented in the WGCNA package^{27,38}. The soft thresholding power ($\beta = 14$) for adjacency
135 calculation was chosen based on approximate scale-free topology before co-expression network
136 construction. The topological overlap matrix (TOM) was built by calculating gene adjacencies using
137 biweight midcorrelation³⁸ with the chosen soft thresholding power, before signed weighted
138 correlation networks were built. Modules were detected via hierarchical gene clustering on TOM-
139 based dissimilarity and branch cutting using the top-down dynamic tree cut method³⁹. Eigengenes
140 were calculated for each module and modules with high eigengene correlations ($r > 0.85$) were
141 merged. Genes not incorporated to any module were assigned to the non-functional grey module. In
142 total 28 functional modules were identified.

143 *Module preservation*

144 $Z_{summary}$ statistics were calculated for module preservation analysis by combining module density-
145 based statistics and intra-modular connectivity-based statistics and separability of modules based
146 on permutation test ($Z = \frac{observed - mean_{permutated}}{sd_{permutated}}$, $Z_{summary} = \frac{Z_{density} + Z_{connectivity}}{2}$). As per the
147 recommended thresholds we defined $Z_{summary} < 2$ as no evidence of preservation, $2 < Z_{summary} <$
148 10 as weak to moderate evidence of preservation and $Z_{summary} > 10$ as strong evidence of
149 preservation⁴⁰.

150 We tested our modules for preservation in an independent dataset, GSE148241⁴¹, which included
151 41 placenta samples (9 with early-onset severe preeclampsia and 32 healthy controls). Only the 32
152 healthy control samples were extracted for use in the analysis. We performed 100 permutations to
153 reconstruct the networks using the same parameters to randomly permute module assignment in
154 the test data.

155 *Gene ontology*

156 Gene ontology enrichment for biological processes was carried out using the Gprofiler online
157 interface with the default settings⁴².

158 *Single cell and cell type enrichment*

159 Cell type enrichment in datasets from Vento-Tormo *et al*¹⁹ and Suryawanshi *et al*²⁰ was carried out
160 using the PlacentaCellEnrich tool⁴³.

161 For single cell co-localization, normalized scRNA seq data from Vento-Tormo *et al* 2018, was
162 downloaded using the Single Cell Browser⁴⁴ (<https://placenta-decidua.cells.ucsc.edu>). Data were
163 then scaled and visualized with Seurat v3.2.3 as previously described⁴⁵. A module score was created
164 using a previously described method⁴⁶.

165 *Transcription factor enrichment analysis*

166 Transcription factor enrichment analysis was performed using the Top Rank method in the ChEA3
167 package using the online interface and default settings⁴⁷.

168 *Genotyping and PGS generation*

169 Genotyping in the GUSTO cohort was performed with the Infinium OmniExpress Exome array.
170 Quality control was done separately for each genetic ancestry. SNPs with a call rate $< 95\%$, minor
171 allele frequency $< 5\%$, that were non-autosomal or that failed the Hardy-Weinberg equilibrium (p -
172 value of 10^{-6}) were removed from the analysis. Variants discordant from their respective
173 subpopulation in the 1000 Genomes Project reference panel were removed (Chinese- EAS with a
174 threshold of 0.20; Indian- SAS with a threshold of 0.20; Malay- EAS with a threshold of 0.30).

175 Samples were removed if they had ancestry or sex discrepancies, call rate < 99% or showed evidence
176 of cryptic relatedness. Data were then pre-phased with SHAPEIT v2.837 with family trio information,
177 and imputation carried out using the Sanger Imputation Service with the 1000G Phase 3 dataset as a
178 reference, using the “with PBWT, no pre-phasing” (the Positional Burrows Wheeler Transform
179 algorithm) pipeline. Imputed SNPs common to all genetic ancestries, which were bi-allelic, non-
180 monomorphic and that had an INFO score > 0.8 were retained for downstream analysis.

181 UK Biobank genotyping and quality control processes are comprehensively described in Bycroft *et al*
182 2018⁴⁸. Participants were excluded from the analysis if consent was withdrawn, genotyping data
183 was unavailable, a genetic kinship to other participants > 0.044 identified, inconsistent genetic and
184 reported sex, or if the subject was an outlier for heterozygosity. We then identified a single
185 participant from each genetic kinship group (genetic relatedness < 0.025), based on their genomic
186 relationship matrix (calculated using Genome-wide Complex Trait Analysis GCTA 1.93.2), which were
187 returned to the analysis.

188 *PGS generation*

189 PGS based on gene lists were generated as previously described^{49–51}. In brief, SNPs located on genes
190 in a relevant list were identified using the biomaRt package^{52,53}. SNPs common with placental eQTLs
191 identified by Peng *et al*, 2017 were retained. These eQTLs were subjected to linkage disequilibrium
192 clumping ($r^2 < 0.2$) in GUSTO and the UK Biobank, leaving only independent loci. For PGS
193 calculation, the number of effect alleles at a particular locus was weighted based on the effect size
194 on gene expression identified by Peng *et al*, before summation within individuals to generate the
195 relevant PGS.

196 PGS for cardiovascular disease (CVD) and major depressive disorder (MDD; without the 23 and me
197 sample) was performed using GWAS summary statistics from Nikpay *et al* 2015 and Howard *et al*
198 2019 using PRSice software v2.2.11.b⁵⁴ at 10 p-value thresholds (0.00000001, 0.0000001, 0.000001,
199 0.00001, 0.0001, 0.001, 0.01, 0.1, 0.2 and 0.5).

200 *Single sample gene set enrichment analysis (ssGSEA)*

201 ssGSEA was implemented through the GSVA package as previously described⁵⁵. Scaled RPKM gene
202 counts were used in the analysis. The effect of the PGS on ssGSEA score in the GUSTO RNA-seq
203 samples was determined through multiple regression using sex and the first 3 genetic principal
204 components as co-variables in the analysis.

205 *Cord blood analysis*

206 Molecular characterization of cord blood from the GUSTO cohort (n=194-251) was conducted in
207 duplicate using commercially available assays. Samples were randomized across plates and internal
208 controls were used to estimate cross-plate variation. Assays with a coefficient of variation exceeding
209 20% across internal standards were excluded. Molecular profiles were analyzed using 1 of 3
210 methods: single molecule array (SIMOA), DropArray and enzyme-linked immunosorbent assay
211 (ELISA). **Table 8** describes the individual assays. SIMOA measurements were made using the SIMOA
212 HD-1 Analyzer (Quanterix). DropArray measurements were made using the FlexMAP3D bead-based
213 multiplex system (Luminex). Normalization was carried out across plates using a median centring
214 method. Data with readings outside of the assay limits as indicated by the manufacturer were
215 discarded.

216 *UK Biobank analysis*

217 All analyses were restricted to unrelated individuals with self-reported sex matching genetically
218 identified sex. Individuals with high genetic missing rates or heterozygosity were also excluded from
219 the analysis.

220 We used the PHESANT package to explore associations with the PGS using a pheWAS framework in
221 the UK Biobank, as described previously⁵⁶. For instances where an outcome was measured multiple
222 times, the variable with highest sample size was retained.

223 *Mendelian Randomization*

224 Mendelian randomization was conducted as previously described using the TwoSampleMR package
225 v0.5.6^{57,58}. In all MR analyses placental eQTLs were used as the exposure. Outcome SNPs from MDD
226⁵⁹, coronary heart disease⁶⁰ and myocardial infarction⁶⁰ GWAS were obtained through the IEU
227 GWAS database. The MDD summary statistics without 23 and me subjects were used in the analysis.
228 Sex-specific GWAS summary statistics for the PHQ-9 in European subjects were downloaded from
229 the Neale lab website⁶¹. Further information on this data can be found in **Table 19**. Exposure and
230 outcome data were harmonized to the same effect allele, with ambiguous SNPs removed from the
231 analysis. We then carried out a fixed effects meta-analysis of the genetic instruments using the IVW
232 (inverse variance weighted) method. These results were then confirmed using the more conservative
233 weighted median method which assumes at least 50% of the instruments used are valid⁶².
234 Heterogeneity and horizontal pleiotropy were then assessed using several methods including the
235 Cochran Q statistic, leave one out analysis, single SNP analysis and the MR egger intercept⁶³⁻⁶⁶

236 *Drug interactions*

237 Drug-gene interactions were interrogated using the online interface of the Drug-Gene Interaction
238 Database v4.2.0⁶⁷.

239 *Enrichment analysis*

240 Enrichment for differentially expressed genes in the cyan module was done using a Fisher's exact
241 test as implemented with the GeneOverlap package⁶⁸.

242 *Network connectivity*

243 To investigate the connectivity of the genes in a particular module we used ARACNE (Algorithm for
244 the Reconstruction of Accurate Cellular Networks⁶⁹) to identify significant gene by gene associations
245 within the modules based on their mutual information. For each ARACNE- derived unweighted
246 network, the connectivity scores of the hub genes were computed.

247 *Statistical analysis*

248 All analysis unless otherwise stated were carried out using R v4.1.1⁷⁰ and Rstudio v1.4.1717⁷¹.
249 Regression analyses were used to analyze the association between the fetoplacental PGS and cord
250 cytokines (GUSTO), ssGSEA (GUSTO) and UK Biobank outcomes using `lm()` or `glm()` functions. Specific
251 covariates for each analysis are described in the dedicated figure legends. The cord blood
252 measurements were log transformed before inclusion in a linear regression analysis with the
253 fetoplacental PGS as the predictor. A significance threshold of 0.05 was used throughout, with the
254 Benjamini-Hochberg method (False Discovery Rate; FDR) used to correct for multiple comparisons.

255 Results

256 *Identification of 28 gene expression modules in term placental villous samples*

257 We used bulk RNA sequencing followed by WGCNA in 44 term placental villous samples obtained as
258 part of the GUSTO study to identify gene expression patterns associated with placental homeostatic
259 inflammation. We sequenced samples consisting of Chinese (26 samples; 59%), Malay (7 samples;
260 16%) and Indian (11 samples; 25%) self-defined ethnicities, with 24 of the 44 sequenced samples
261 being female. Sample characteristics are shown in **Table 1**.

262 Following hierarchical clustering of the RNA sequencing data, 2 samples were removed as putative
263 outliers (**Figure S1A**) and 42 samples were submitted to WGCNA. From 31,097 expressed genes we
264 identified 28 gene expression module (**Figure 1A**), ranging in size from 72 (skyblue module) to 6794
265 genes (turquoise module). Unassigned genes were grouped into the grey module, with the
266 constituents of each module comprehensively described in **Table 2**.

267

268 *Identification and characterization of a module related to homeostatic inflammation in the placental villous*

270 The cyan module contained 486 genes (**Figure S1B**) and gene ontology analysis indicated a strong
271 association with inflammation (**Figure 1B; Table 3**). The cyan module was also strongly preserved in
272 an independent dataset⁴¹ (**Figure S1C**). Several well characterized inflammation-related genes were
273 present in the module including members of the tumor necrosis factor (*TNFRSF11A*, *TNFAIP8L2*,
274 *TNFRSF21*, *TNFSF13*, *TNFSF9*) and interleukin (*IL2RA*, *IL12RB2*, *IL1RL1*) families, as well as several
275 genes associated with the myeloid lineage (*AIF1*, *CSF1*, *CD33*, *CD163*). We found no evidence for a
276 correlation between the cyan module expression and fetal sex ($r = -0.037$; $p = 0.8$).

277 Single-cell RNA sequencing data from the human placenta^{19,20} showed cyan module genes were
278 primarily expressed within Hofbauer cells (**Figure 1C and Figure S2A and 2B**), a fetal macrophage
279 population localized to the placental villous^{72,73}. Transcription factor enrichment analysis also
280 identified targets of transcription factors associated with macrophage identity, including *SPI1* and
281 *MAFB*, as enriched within the cyan module (**Figure S2C**). Hofbauer cells are the predominant fetal
282 immune cell in the placenta²² with important homeostatic^{22,24-26} and pathogenic roles^{22,23}. As such
283 the cyan module presented an excellent candidate for further investigation.

284 We next used a placental eQTL resource from Peng *et al*²⁸ to identify SNPs contributing to variation
285 in expression of cyan module genes (**Table 4**). In a comparison with the Gene-Tissue Expression
286 (GTEx) v8 eQTL catalogue⁷⁴, the combination of these eQTLs associated with cyan module genes
287 were highly specific to the placenta (**Figure S1D**). We then identified these variants in the children of
288 the GUSTO cohort and weighted them based on their effect size from Peng *et al*, before summing
289 them within individuals to create a fetoplacental PGS (as described previously^{49,50}). We reasoned
290 that a PGS comprised of eQTLs would be representative of individual variation in cyan module
291 expression. We validated this assumption using single sample gene set enrichment analysis in the
292 GUSTO RNA-seq dataset ($p = 0.003$, $\beta = 0.02$, $N = 42$; **Figure 1D**). A higher PGS score was associated with
293 increased expression of cyan module genes. The cyan module PGS did not predict the expression of
294 the other WGCNA modules (**Table 5**) and a PGS created in a similar fashion, using the WGCNA
295 modules closest in size to the cyan module, had no effect on expression of cyan module genes
296 (**Figure 1D; Table 6**). We provided additional controls for specificity by creating 2 PGSs based on
297 randomly generated lists of 486 genes (same size of the cyan module) from our sequencing dataset

298 and another using the cyan module but weighting it with eQTLs from fetal cortical tissue⁷⁵. None of
299 these PGSs predicted expression of the cyan module ($p=0.11$, 0.61 and 0.19 , respectively; **Figure 1D**).
300 Taken together these findings suggest the fetoplacental PGS has considerable specificity for genes
301 comprising the module.

302 Correlation analysis in the GUSTO cohort showed the fetoplacental PGS was not correlated with
303 various perinatal factors (**Figure S1E**) including measures of maternal mental health, gestational age
304 at birth, birth weight, offspring sex and socio-economic status.

305 Considering the importance of secreted factors during fetal development, we next investigated the
306 association of the fetoplacental PGS with 27 cord blood molecules. These factors included cytokines
307 (e.g. TNF α and IL6) and hormones (e.g. testosterone and insulin) with well-established prenatal
308 effects. Using the fetoplacental PGS allowed us to expand our investigation to the entire sample of
309 the GUSTO cohort with available genotype and cord blood data ($n=194-251$). Using the fetoplacental
310 PGS as the predictor in a multiple regression analysis, the strongest effect was an association with
311 monocyte chemoattractive protein 1 (MCP-1, also known as CCL-2; $p=0.005$, $\beta=0.14$; **Figure 1E**;
312 **Table 7**). Interestingly, Hofbauer cells secrete high levels of MCP-1²², indicating our fetoplacental
313 PGS may reflect Hofbauer cell function.

314

315 *Phenome-wide association study identifies adult cardiometabolic and mental health related*
316 *outcomes are associated with the fetoplacental PGS*

317 There is a paucity of studies that have evaluated placental contributions to adult outcomes of the
318 offspring in large human datasets. We therefore created a PGS in the UK Biobank, using identical
319 criteria to the previously described fetoplacental PGS in the GUSTO cohort. We used this PGS to
320 perform a pheWAS with 1831 traits as outcomes of interests. Only unrelated individuals were used
321 and outcomes were categorized to an appropriate regression family using the PHEASANT package⁵⁶.
322 We identified 21 significant associations (FDR p -value < 0.05 ; **Figure 2A**; **Table 9**) that were primarily
323 localized to the cardiometabolic and mental health domains. All traits associated within the
324 cardiometabolic domain had a positive direction of effect and all traits within the mental health
325 domain had a negative direction of effect (**Table 9**). When samples were split by sex, no association
326 passed the threshold for multiple comparisons, but both cardiometabolic and mental health traits
327 approached the threshold for multiple comparisons in each sex (**Table 10 and 11**).

328 Considering the striking enrichment of traits in the cardiometabolic and mental health domains, we
329 next examined the association between the fetoplacental PGS and diagnoses within these domains.
330 We considered 66 cardiometabolic and mental health diagnoses in the analysis and evaluated their
331 association with the PGS in males, females and combined samples. We used logistic regression and
332 identified 5 significant associations (FDR p -value <0.05), all of which were in females (**Figure 2B**;
333 **Table 12-14**). Of these 5 associations, 4 pertained to mental health (“Any mental health problem”;
334 FDR=0.049, $\beta=-0.022$, “Mood and anxiety disorders”; FDR=0.049, $\beta=-0.022$, “Mood disorder”;
335 FDR=0.049, $\beta=-0.024$, and “Depression”; FDR=0.049, $\beta=-0.024$) and 1 to the cardiometabolic domain
336 (“Chronic ischemic heart disease”; FDR=0.049, $\beta=0.044$). Depression was the most frequent
337 diagnosis included under the 3 more broad mental health categorizations. We thus focused our
338 subsequent analysis on depression and chronic ischemic heart disease. In line with our pheWAS
339 results, the fetoplacental PGS had a protective effect for depression and acted to increase the risk
340 for chronic ischemic heart disease. There was no correlation between our fetoplacental PGS and
341 polygenic risk scores (PRS) for depression or cardiovascular disease (**Figure S3**). Furthermore, the

342 associations remained significant when a PRS for the relevant condition was used as a covariate in
343 the analysis (**Figure S4**). The associations also remained significant when a diagnosis of depression or
344 chronic ischemic heart disease was used as a covariate in the analysis of the other (**Figure S4**). These
345 findings suggest our results are not the product of genetic architecture that overlaps with the
346 relevant condition.

347

348 *Mendelian randomization identifies a protective effect of placental eQTLs for cardiovascular disease*
349 *and suicidality in females*

350 We next used Mendelian randomization as implemented in the TwosampleMR package^{57,58}. We
351 used the eQTLs that composed the fetoplacental PGS as genetic instruments and the inverse
352 variance weighted (IVW) method to estimate effects on both coronary heart disease and myocardial
353 infarction⁶⁰. Contrary to our results using regression analyses, Mendelian randomization showed a
354 protective effect on both outcomes (coronary heart disease, $p=0.002$, $\beta=-0.009$; myocardial
355 infarction, $p=0.003$, $\beta=-0.009$; **Figure 2C; Tables 15**). The effect on myocardial infarction was
356 confirmed with the weighted median method ($p=0.01$, $\beta=-0.01$), while coronary heart disease fell on
357 the threshold for significance using this method ($p=0.05$, $\beta=-0.008$) (**Figure S5A and S6A; Table 16**).
358 In supplementary analyses we found no evidence of instrument heterogeneity or horizontal
359 pleiotropy using the Cochrane's Q test, leave one out analysis, single SNP analysis and the MR egger
360 intercept (**Tables 17 and 18; Figure S5B and S5C; Figure S6B and S6C**). This protective effect is in
361 contrast to the increased risk we observed with regression analyses and underlines the importance
362 of using orthogonal methods, such as mendelian randomization, that are more robust to
363 environmental confounding.

364 Similar analysis for MDD also suggested a protective effect of the eQTLs, but was marginally outside
365 the threshold for statistical significance using both the IVW ($p=0.08$, $\beta=-0.003$) and weighted median
366 ($p=0.08$, $\beta=-0.003$) methods (**Figure 2C and S7; Table 15 and 16**). We reasoned this may either be
367 due to sex-dependent effects, as observed in our logistic regression analysis, or to symptom specific
368 effects. To address these questions we ran Mendelian randomization analyses using sex-specific
369 GWAS summary statistics from the patient health questionnaire 9 (PHQ-9), answered as part of the
370 UK Biobank^{61,76}. The PHQ-9 is a self-report questionnaire based on the 9 DSM criteria for a diagnosis
371 of depression (**Table 19**). In this analysis, we identified a robust protective effect for suicidality in
372 females ($p=0.003$, $FDR=0.02$, $\beta=-0.001$; **Figure 2C; Table 15**). This finding was confirmed with the
373 weighted median method ($p=0.04$, $\beta=-0.001$; **Table 16**), with no evidence of heterogeneity or
374 horizontal pleiotropy (**Figure S8; Table 17 and 18**). We also identified a significant effect in the full
375 sample for suicidality using the IVW method, but this could not be confirmed by the weighted
376 median method (**Figure S9; Table 17 and 18**).

377 These results demonstrate our expression signature of homeostatic inflammation in the placenta is
378 protective against adult cardiovascular disease in a male/female combined sample and against
379 suicidal ideation in females. These results are in line with a large body of literature describing a
380 positive correlation between cardiovascular and depressive risk^{77,78}.

381

382 *Cyan module is highly enriched for genes differentially regulated by intra-uterine infection and*
383 *preterm birth*

384 Interestingly, previous work in populations exposed to instances of pathogenic inflammation, such
385 as preterm birth or general prenatal infection, have shown an *increased* risk for both cardiovascular
386 disease and depressive outcomes^{29–33}. This is in contrast to our findings, where we see *protective*
387 effects of homeostatic inflammation on these outcomes. A parsimonious explanation for this is that
388 pathological prenatal exposures may partly confer risk for adult health outcomes by disrupting the
389 homeostatic function of inflammation related gene expression in the placenta.

390 Therefore, we next asked whether placental genes differentially regulated by preterm birth,
391 infection or other exposures were enriched within the cyan module. We mined the published
392 literature for studies that performed differential expression analysis in the human placenta following
393 various exposures^{79–85} and extracted differentially expressed genes. We found a very strong
394 enrichment of genes differentially expressed in response to intra-amniotic infection (154 genes;
395 $p=5.2e-15$) and preterm birth (15 genes; $p=2.6e-05$) in the cyan module (**Figure 3A; Table 20**). We
396 then used ARACNE⁶⁹ to measure the connectivity of all genes within the cyan module and estimated
397 the degree of connectivity in genes differentially regulated by intra-amniotic infection or preterm
398 birth. This approach showed these genes were critical regulators of cyan module integrity and
399 suggests severe disruption of the cyan module occurs with intra-amniotic infection (**Figure 3C; Table**
400 **21**).

401 We finally asked if any drugs are known to target genes of the cyan module. We used DGIdb,
402 which compiles gene expression effects of drugs. This unbiased analysis identified the anti-
403 inflammatory drug, aspirin, as the drug with the most targets within the cyan module (**Figure 3B**).
404 Characterizing the connectivity of these genes demonstrated their essential importance to the
405 module (**Figure 3C; Table 21**) and the potential for aspirin to modulate cyan module integrity.

406 Our data advocate for a mechanism by which intra-uterine infection and preterm birth confer risk
407 for cardiovascular and depressive outcomes, at least partially, through disruption or loss of the
408 homeostatic functions of the cyan module and the cell type within which it is primarily expressed,
409 Hofbauer cells.

410

411

412 Discussion

413 We used a multi-modal approach integrating transcriptomics, genetics and adult health outcomes
414 across multiple cohorts and genetic ancestries to assess the effect of homeostatic placental
415 inflammation on adult offspring outcomes. We used distinct complementary methods and several
416 supplementary analyses to identify a novel protective effect of a placental gene co-expression
417 module, principally expressed in Hofbauer cells, on adult depressive and cardiovascular outcomes.
418 Our results suggest disruption or loss of the homeostatic functions served by Hofbauer cells may
419 contribute to the increased risk of adult cardiovascular and depressive outcomes in individuals
420 exposed to intra-uterine infection or born preterm.

421 Intra-uterine infection is a primary precipitant of preterm birth⁸⁶, which in turn is associated with a
422 marked increase in risk for adult depression and cardiovascular disease^{29–31}. Loss of the placenta and
423 therefore Hofbauer cell function, is an inevitable consequence of preterm birth. A model under
424 which this premature loss of Hofbauer cell function contributes to adverse adult health outcomes in
425 offspring is plausible. Indeed similar mechanisms have been described for several placental
426 mechanisms, with particularly strong evidence for endocrine functions^{87,88}. Our cord blood analysis
427 found the strongest association between the fetoplacental PGS and MCP-1, suggesting that it (or
428 indeed other unmeasured secreted molecules) could act to stimulate fetal development. Premature
429 cessation of this endocrine signalling may then contribute to adverse adult health outcomes in
430 offspring. Hofbauer cells are understudied and future comprehensive characterizations of their
431 function throughout pregnancy would likely further inform these mechanisms and may even point to
432 novel therapeutic or preventive strategies in preterm infants.

433 Intra-uterine infection can also occur in pregnancies carried to term, but adult outcomes of this
434 population is less studied. Population studies that do not discriminate between maternally confined
435 and intra-amniotic infections have observed an increased risk for both depression and cardiovascular
436 disease in offspring^{32,33}, but future work stratifying by infection type will be critical. In our study, the
437 transcriptional response to intra-uterine infection was highly enriched within our Hofbauer gene
438 expression module. These genes in turn were central components of the network, suggesting severe
439 disruption in instances of intra-uterine infection. Histological studies have indeed seen changes in
440 Hofbauer cell distribution with intra-uterine infection⁸⁹. Hofbauer cells also express physiologically
441 functional Toll Like Receptors, suggesting an active role in the response to intra-amniotic infection²².
442 Previous studies have even observed direct infection of Hofbauer cells by HIV, Zika and SARS-CoV-2
443 viruses^{90–92}. Together, this suggests a novel clinical approach to reducing risk of adverse offspring
444 health outcomes following intra-amniotic infection may be to target the cyan module and Hofbauer
445 cells.

446 Of the drugs annotated in the DGIdb, the anti-inflammatory drug, aspirin, had the most targets in
447 the cyan module. Even though these genes represented only a minority of the module's membership
448 the genes showed a very high degree of connectivity, indicating their potential to affect network
449 integrity. Aspirin is an attractive candidate considering its breadth of use and volume of available
450 data. In fact, aspirin is already recommended for use in pregnant women at high risk of preeclampsia
451^{93,94}, and estimates suggest it is already used by up to 38.8% of this population in the United States
452⁹⁵. It is unknown if aspirin therapeutically acts through Hofbauer cells in the context of preeclampsia,
453 but a previously characterized function of Hofbauer cells is in angiogenesis. Disruptions in placental
454 angiogenesis have also been observed with prenatal infection (reviewed by Weckman *et al.*, 2019)
455 and MCP-1, which we found to have the strongest association with the fetoplacental PGS in cord
456 blood, is also an angiogenic regulator^{97,98}. A credible hypothesis based on our results is that intra-
457 amniotic infection elicits a response from Hofbauer cells, which perturbs placental angiogenesis with

458 long-term consequences for the fetus. The effects of aspirin on the cyan module, Hofbauer cell
459 function, angiogenesis and ultimately whether it is beneficial for pregnancies at risk of intra-uterine
460 infection, are key future questions.

461 We found several instances of sex-dependent effects in our study. This is not surprising, as sex
462 differences in the prevalence of depression^{99,100} and cardiovascular disease¹⁰¹ have been widely
463 reported. These conditions are also highly comorbid and genetically correlated^{77,78,102}. Our results
464 provide evidence that sexually dimorphic regulation of risk for these outcomes starts during early
465 development. We did not identify any correlation of cyan module expression with fetal sex and
466 previous studies in other tissues have not observed notable sex-biases in eQTLs¹⁰³. Therefore, we
467 have no evidence to suggest sex biases were present in our analyses at either the gene expression
468 level or eQTL level. Processes downstream of the cyan module are then likely responsible for these
469 sex-differences, but future work is required to establish the nature of these processes.

470 **Limitations**

471 Our study has limitations that must be considered. First, our analysis was limited by the availability
472 of placental functional genomic resources. Future studies with increased power for placental eQTL
473 discovery are essential to increase the discovery power of studies such as ours. Second, due to the
474 nature of many large GWASes, summary statistics were often only available for males and females
475 combined. As GWAS sample size increases, we anticipate the wider availability of sex-specific
476 summary statistics will further expand the study of sex differences into powerful methods like
477 Mendelian randomization. Finally, we confined our RNA sequencing samples to term births to avoid
478 pathological artifacts associated with preterm birth. Characterizing the developmental expression
479 trajectories of homeostatic inflammation patterns in the placenta will be an important future step.

480 **Conclusions**

481 In conclusion, we identified a gene expression module related to homeostatic inflammation in the
482 placenta that was highly enriched in Hofbauer cells, and created a PGS that specifically predicted
483 expression of this module. We used this PGS to identify associations with traits in the
484 cardiometabolic and mental health domains of the UK Biobank. Follow-up analyses using logistic
485 regression and Mendelian randomization demonstrated genetically-inferred cyan module expression
486 was protective for cardiovascular and depressive outcomes. We finally showed that genes
487 differentially regulated by both intra-amniotic infection and preterm birth were highly enriched in
488 the cyan module. These findings suggest that loss of Hofbauer cell function with preterm birth or its
489 disruption with intra-amniotic infection may contribute to the increased risk of cardiovascular
490 disease and depression in these offspring.

491

492

493 **Author contributions**

494 EF planned the study, performed the analysis, interpreted the data and wrote the initial draft of the
495 manuscript, with editing from MJM who provided funding. HC provided feedback on the manuscript.
496 MJS performed WGCNA. HEJY and PL coordinated and prepared placental samples for RNA-seq. SYC
497 oversaw the sample selection for RNA-seq. Placentas were collected in accordance with protocols
498 developed by JC. RNA-seq data were analyzed by EF, NOT and MJM. Calculation of PGS was
499 performed by ZW, SP and IP. YSC, PDG and MJM designed the GUSTO cohort study and obtained
500 funding. All authors approved the final version of the manuscript.

501 **Competing interests**

502 The authors have no competing interests to declare.

503 **Funding statement**

504 Funding for this study was provided through funding of the Depression Task Force of the Hope for
505 Depression Research Foundation to MJM.

506 **Data availability**

507 Access to data from the GUSTO and UK Biobank are dependent on approved application to the
508 respective data access committees. All other data generated in this study are provided in the
509 supplementary material.

510 **Code availability**

511 Code for these analyses was in line with vignettes for all packages mentioned in the methods. Code
512 to run the pheWAS analysis can be found at <https://github.com/MRCIEU/PHEASANT>. Code to run the
513 Mendelian randomization analysis can be found at <https://mrcieu.github.io/TwoSampleMR/>.

514 **Acknowledgments**

515 We would like to acknowledge both the GUSTO and UK Biobank investigators, staff, researchers and
516 in particular the participants. This research has been conducted using the UK Biobank Resource
517 under Application Number 41975.

518 References

- 519 1. Barker, D. J. P., Osmond, C., Winter, P. D., Margetts, B. & Simmonds, S. J. Weight in infancy
520 and death from ischaemic heart disease. *Lancet (London, England)* **2**, 577–580 (1989).
- 521 2. Martyn, C. N., Barker, D. J. P. & Osmond, C. Mothers' pelvic size, fetal growth, and death from
522 stroke and coronary heart disease in men in the UK. *Lancet* **348**, 1264–1268 (1996).
- 523 3. Forsén, T. *et al.* Mother's weight in pregnancy and coronary heart disease in a cohort of
524 finnish men: follow up study. *BMJ* **315**, 837–840 (1997).
- 525 4. Barker, D. J. P. & Osmond, C. Infant mortality, childhood nutrition, and ischaemic heart
526 disease in England and Wales. *Lancet (London, England)* **1**, 1077–1081 (1986).
- 527 5. O'Donnell, K. J. & Meaney, M. J. Fetal origins of mental health: The developmental origins of
528 health and disease hypothesis. *Am. J. Psychiatry* **174**, 319–328 (2017).
- 529 6. Gluckman, P. D. & Hanson, M. A. The Developmental Origins of Health and Disease: The
530 Breadth and Importance of the Concept. (2006).
- 531 7. Goldstein, J. A., Gallagher, K., Beck, C., Kumar, R. & Gernand, A. D. Maternal-Fetal
532 Inflammation in the Placenta and the Developmental Origins of Health and Disease. *Front.*
533 *Immunol.* **11**, 2786 (2020).
- 534 8. Davis, J. O., Phelps, J. A. & Bracha, H. S. Prenatal Development of Monozygotic Twins and
535 Concordance for Schizophrenia. *Schizophr. Bull.* **21**, 357–366 (1995).
- 536 9. Boix, C. A., James, B. T., Park, Y. P., Meuleman, W. & Kellis, M. Regulatory genomic circuitry of
537 human disease loci by integrative epigenomics. *Nat. 2021 5907845* **590**, 300–307 (2021).
- 538 10. Ursini, G. *et al.* Placental genomic risk scores and early neurodevelopmental outcomes. *Proc.*
539 *Natl. Acad. Sci. U. S. A.* **118**, (2021).
- 540 11. Ursini, G. *et al.* Convergence of placenta biology and genetic risk for schizophrenia. *Nat. Med.*
541 *2018 246* **24**, 792–801 (2018).
- 542 12. Bhattacharya, A. *et al.* Placental genomics mediates genetic associations with complex health
543 traits and disease. *Nat. Commun. 2022 131* **13**, 1–15 (2022).
- 544 13. O'Connor, T. G. & Ciesla, A. A. Maternal Immune Activation Hypotheses for Human
545 Neurodevelopment: Some Outstanding Questions. *Biol. Psychiatry Cogn. Neurosci.*
546 *Neuroimaging* (2021) doi:10.1016/J.BPSC.2021.10.006.
- 547 14. Megli, C. J. & Coyne, C. B. Infections at the maternal–fetal interface: an overview of
548 pathogenesis and defence. *Nat. Rev. Microbiol. 2021 202* **20**, 67–82 (2021).
- 549 15. Wu, W. L., Hsiao, E. Y., Yan, Z., Mazmanian, S. K. & Patterson, P. H. The placental interleukin-6
550 signaling controls fetal brain development and behavior. *Brain. Behav. Immun.* **62**, 11–23
551 (2017).
- 552 16. Hsiao, E. Y. & Patterson, P. H. Activation of the maternal immune system induces endocrine
553 changes in the placenta via IL-6. *Brain. Behav. Immun.* **25**, 604–615 (2011).
- 554 17. Estes, M. L. & McAllister, A. K. Maternal immune activation: Implications for neuropsychiatric
555 disorders. *Science (80-.)*. **353**, 772–777 (2016).
- 556 18. Han, V. X., Patel, S., Jones, H. F. & Dale, R. C. Maternal immune activation and
557 neuroinflammation in human neurodevelopmental disorders. *Nat. Rev. Neurol.* *2021 179* **17**,
558 564–579 (2021).

- 559 19. Vento-Tormo, R. *et al.* Single-cell reconstruction of the early maternal–fetal interface in
560 humans. *Nat.* 2018 5637731 **563**, 347–353 (2018).
- 561 20. Suryawanshi, H. *et al.* A single-cell survey of the human first-trimester placenta and decidua.
562 *Sci. Adv.* **4**, (2018).
- 563 21. Bilimoria, P. M. & Stevens, B. Microglia function during brain development: New insights from
564 animal models. *Brain Res.* **1617**, 7–17 (2015).
- 565 22. Thomas, J. R. *et al.* Phenotypic and functional characterization of first-trimester human
566 placental macrophages, Hofbauer cells. *J. Exp. Med.* **218**, (2020).
- 567 23. Anteby, E. Y. *et al.* Human Placental Hofbauer Cells Express Sprouty Proteins: a Possible
568 Modulating Mechanism of Villous Branching. *Placenta* **26**, 476–483 (2005).
- 569 24. Reyes, L. & Golos, T. G. Hofbauer cells: Their role in healthy and complicated pregnancy.
570 *Front. Immunol.* **9**, 2628 (2018).
- 571 25. Schwartz, D. A. Viral infection, proliferation, and hyperplasia of Hofbauer cells and absence of
572 inflammation characterize the placental pathology of fetuses with congenital Zika virus
573 infection. *Arch. Gynecol. Obstet.* **295**, 1361–1368 (2017).
- 574 26. Satosar, A., Ramirez, N. C., Bartholomew, D., Davis, J. & Nuovo, G. J. Histologic correlates of
575 viral and bacterial infection of the placenta associated with severe morbidity and mortality in
576 the newborn. *Hum. Pathol.* **35**, 536–545 (2004).
- 577 27. Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation network analysis.
578 *BMC Bioinformatics* **9**, 1–13 (2008).
- 579 28. Peng, S. *et al.* Expression quantitative trait loci (eQTLs) in human placentas suggest
580 developmental origins of complex diseases. *Hum. Mol. Genet.* **26**, 3432 (2017).
- 581 29. Markopoulou, P., Papanikolaou, E., Analytis, A., Zoumakis, E. & Sihanidou, T. Preterm Birth
582 as a Risk Factor for Metabolic Syndrome and Cardiovascular Disease in Adult Life: A
583 Systematic Review and Meta-Analysis. *J. Pediatr.* **210**, 69-80.e5 (2019).
- 584 30. Nosarti, C. *et al.* Preterm Birth and Psychiatric Disorders in Young Adult Life. *Arch. Gen.*
585 *Psychiatry* **69**, 610–617 (2012).
- 586 31. Upadhyaya, S. *et al.* Preterm Birth Is Associated With Depression From Childhood to Early
587 Adulthood. *J. Am. Acad. Child Adolesc. Psychiatry* **60**, 1127–1136 (2021).
- 588 32. Al-Haddad, B. J. S. S. *et al.* Long-term Risk of Neuropsychiatric Disease After Exposure to
589 Infection In Utero. *JAMA Psychiatry* **76**, 594–602 (2019).
- 590 33. Mazumder, B., Almond, D., Park, K., Crimmins, E. M. & Finch, C. E. Lingering prenatal effects
591 of the 1918 influenza pandemic on cardiovascular disease. *J. Dev. Orig. Health Dis.* **1**, 26–34
592 (2010).
- 593 34. Ng, S. *et al.* High maternal circulating cotinine during pregnancy is associated with
594 persistently shorter stature from birth to five years in an Asian cohort. *Nicotine Tob. Res.* **21**,
595 1103–1112 (2019).
- 596 35. Andrews, S. Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput
597 Sequence Data. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (2010).
- 598 36. Ewels, P., Magnusson, M., Lundin, S. & Källér, M. MultiQC: summarize analysis results for
599 multiple tools and samples in a single report. *Bioinformatics* **32**, 3047–3048 (2016).

- 600 37. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 601 38. Langfelder, P. & Horvath, S. Fast R Functions for Robust Correlations and Hierarchical
602 Clustering. *J. Stat. Softw.* **46**, 1–17 (2012).
- 603 39. Langfelder, P., Zhang, B. & Horvath, S. Defining clusters from a hierarchical cluster tree: the
604 Dynamic Tree Cut package for R. *Bioinformatics* **24**, 719–720 (2008).
- 605 40. Langfelder, P., Luo, R., Oldham, M. C. & Horvath, S. Is My Network Module Preserved and
606 Reproducible? *PLOS Comput. Biol.* **7**, e1001057 (2011).
- 607 41. Yang, X. *et al.* Landscape of Dysregulated Placental RNA Editing Associated with Preeclampsia.
608 *Hypertension* **75**, 1532–1541 (2020).
- 609 42. Raudvere, U. *et al.* g:Profiler: a web server for functional enrichment analysis and conversions
610 of gene lists (2019 update). *Nucleic Acids Res.* **47**, W191–W198 (2019).
- 611 43. Jain, A. & Tuteja, G. PlacentaCellEnrich: A tool to characterize gene sets using placenta cell-
612 specific gene enrichment analysis. *Placenta* **103**, 164–171 (2021).
- 613 44. Speir, M. L. *et al.* UCSC Cell Browser: visualize your single-cell data. *Bioinformatics* **37**, 4578–
614 4580 (2021).
- 615 45. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
616 transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.*
617 **36**, 411–420 (2018).
- 618 46. Tirosh, I. *et al.* Dissecting the multicellular ecosystem of metastatic melanoma by single-cell
619 RNA-seq. *Science (80-.)*. **352**, 189–196 (2016).
- 620 47. Keenan, A. B. *et al.* ChEA3: transcription factor enrichment analysis by orthogonal omics
621 integration. *Nucleic Acids Res.* **47**, W212–W224 (2019).
- 622 48. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nat.*
623 *2018 5627726* **562**, 203–209 (2018).
- 624 49. Restrepo-Lozano, J. M. *et al.* Corticolimbic DCC gene co-expression networks as predictors of
625 impulsivity in children. *Mol. Psychiatry* **2022** 1–9 (2022) doi:10.1038/s41380-022-01533-7.
- 626 50. Hari Dass, S. A. *et al.* A biologically-informed polygenic score identifies endophenotypes and
627 clinical conditions associated with the insulin receptor function on specific brain regions.
628 *EBioMedicine* **42**, 188–202 (2019).
- 629 51. Miguel, P. M. *et al.* Prefrontal Cortex Dopamine Transporter Gene Network Moderates the
630 Effect of Perinatal Hypoxic-Ischemic Conditions on Cognitive Flexibility and Brain Gray Matter
631 Density in Children. *Biol. Psychiatry* **86**, 621–630 (2019).
- 632 52. Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the integration of
633 genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **2009 48 4**, 1184–
634 1191 (2009).
- 635 53. Durinck, S. *et al.* BioMart and Bioconductor: a powerful link between biological databases and
636 microarray data analysis. *Bioinformatics* **21**, 3439–3440 (2005).
- 637 54. Choi, S. W. & O’Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-scale data.
638 *Gigascience* **8**, (2019).
- 639 55. Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for microarray
640 and RNA-Seq data. *BMC Bioinformatics* **14**, 1–15 (2013).

- 641 56. Millard, L. A. C., Davies, N. M., Gaunt, T. R., Smith, G. D. & Tilling, K. Software Application
642 Profile: PHESANT: a tool for performing automated phenome scans in UK Biobank. *Int. J.*
643 *Epidemiol.* **47**, 29–35 (2018).
- 644 57. Hemani, G. *et al.* The MR-base platform supports systematic causal inference across the
645 human phenome. *Elife* **7**, (2018).
- 646 58. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
647 imprecisely measured traits using GWAS summary data. *PLOS Genet.* **13**, e1007081 (2017).
- 648 59. Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102 independent
649 variants and highlights the importance of the prefrontal brain regions. *Nat. Neurosci.* **2019**
650 **22**, 343–352 (2019).
- 651 60. Nikpay, M. *et al.* A comprehensive 1,000 Genomes-based genome-wide association meta-
652 analysis of coronary artery disease. *Nat. Genet.* **47**, 1121–1130 (2015).
- 653 61. UK Biobank — Neale lab. <http://www.nealelab.is/uk-biobank/>.
- 654 62. Burgess, S., Small, D. S. & Thompson, S. G. A review of instrumental variable estimators for
655 Mendelian randomization. *Stat. Methods Med. Res.* **26**, 2333–2355 (2017).
- 656 63. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a
657 guide, glossary, and checklist for clinicians. *BMJ* **362**, 601 (2018).
- 658 64. Greco M, F. Del, Minelli, C., Sheehan, N. A. & Thompson, J. R. Detecting pleiotropy in
659 Mendelian randomisation studies with summary data and a continuous outcome. *Stat. Med.*
660 **34**, 2926–2940 (2015).
- 661 65. Bowden, J., Smith, G. D. & Burgess, S. Mendelian randomization with invalid instruments:
662 effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* **44**, 512–525
663 (2015).
- 664 66. Burgess, S. & Thompson, S. G. Interpreting findings from Mendelian randomization using the
665 MR-Egger method. *Eur. J. Epidemiol.* **32**, 377–389 (2017).
- 666 67. Freshour, S. L. *et al.* Integration of the Drug–Gene Interaction Database (DGIdb 4.0) with
667 open crowdsource efforts. *Nucleic Acids Res.* **49**, D1144–D1151 (2021).
- 668 68. Shen, L. GeneOverlap: R package for testing and visualizing gene list overlaps.
669 <https://github.com/shenlab-sinai/geneoverlap>.
- 670 69. Margolin, A. A. *et al.* ARACNE: An algorithm for the reconstruction of gene regulatory
671 networks in a mammalian cellular context. *BMC Bioinformatics* **7**, 1–15 (2006).
- 672 70. R Core Team. R: The R Project for Statistical Computing. (2021).
- 673 71. RStudio Team. RStudio: Integrated Development for R. (2020).
- 674 72. Kim, J. S. *et al.* Involvement of Hofbauer cells and maternal T cells in villitis of unknown
675 aetiology. *Histopathology* **52**, 457–464 (2008).
- 676 73. Reyes, L. *et al.* Hofbauer Cells: Placental Macrophages of Fetal Origin. *Results Probl. Cell*
677 *Differ.* **62**, 45–60 (2017).
- 678 74. Aguet, F. *et al.* The impact of sex on gene expression across human tissues. *Science (80-)*.
679 **369**, (2020).
- 680 75. Walker, R. L. *et al.* Genetic Control of Expression and Splicing in Developing Human Brain

- 681 Informs Disease Mechanisms. *Cell* **179**, 750-771.e22 (2019).
- 682 76. Davis, K. A. S. *et al.* Mental health in UK Biobank – development, implementation and results
683 from an online questionnaire completed by 157 366 participants: a reanalysis. *BJPsych Open*
684 **6**, (2020).
- 685 77. Nemeroff, C. B. & Goldschmidt-Clermont, P. J. Heartache and heartbreak—the link between
686 depression and cardiovascular disease. *Nat. Rev. Cardiol.* **2012 99 9**, 526–539 (2012).
- 687 78. Lu, Y., Wang, Z., Georgakis, M. K., Lin, H. & Zheng, L. Genetic liability to depression and risk of
688 coronary artery disease, myocardial infarction, and other cardiovascular outcomes. *J. Am.*
689 *Heart Assoc.* **10**, 1–8 (2021).
- 690 79. Motomura, K. *et al.* RNA sequencing reveals distinct immune responses in the chorioamniotic
691 membranes of women with preterm labor and microbial or sterile intra-amniotic
692 inflammation. *Infect. Immun.* **89**, (2021).
- 693 80. Söber, S. *et al.* Extensive shift in placental transcriptome profile in preeclampsia and placental
694 origin of adverse pregnancy outcomes. *Sci. Rep.* **5**, (2015).
- 695 81. Gonzalez, T. L. *et al.* Sex differences in the late first trimester human placenta transcriptome.
696 *Biol. Sex Differ.* **9**, (2018).
- 697 82. Gong, S. *et al.* The RNA landscape of the human placenta in health and disease. *Nat.*
698 *Commun.* **2021 121 12**, 1–17 (2021).
- 699 83. Litzky, J. F. *et al.* Prenatal exposure to maternal depression and anxiety on imprinted gene
700 expression in placenta and infant neurodevelopment and growth. *Pediatr. Res.* **2018 835 83**,
701 1075–1083 (2018).
- 702 84. Pereyra, S., Sosa, C., Bertoni, B. & Sapiro, R. Transcriptomic analysis of fetal membranes
703 reveals pathways involved in preterm birth. *BMC Med. Genomics* **2019 121 12**, 1–14 (2019).
- 704 85. Nomura, Y. *et al.* Natural disaster stress during pregnancy is linked to reprogramming of the
705 placenta transcriptome in relation to anxiety and stress hormones in young offspring. **26**,
706 (2021).
- 707 86. Galinsky, R., Polglase, G. R., Hooper, S. B., Black, M. J. & Moss, T. J. M. The consequences of
708 chorioamnionitis: Preterm birth and effects on development. *J. Pregnancy* **2013**, (2013).
- 709 87. Kratimenos, P. & Penn, A. A. Placental programming of neuropsychiatric disease. *Pediatr. Res.*
710 **86**, 157–164 (2019).
- 711 88. Vacher, C. M. *et al.* Placental endocrine function shapes cerebellar development and social
712 behavior. *Nat. Neurosci.* **2021 2410 24**, 1392–1401 (2021).
- 713 89. Zulu, M. Z., Martinez, F. O., Gordon, S. & Gray, C. M. The Elusive Role of Placental
714 Macrophages: The Hofbauer Cell. *J. Innate Immun.* **11**, 447 (2019).
- 715 90. Quicke, K. M. *et al.* Zika Virus Infects Human Placental Macrophages. *Cell Host Microbe* **20**,
716 83–90 (2016).
- 717 91. Johnson, E. L., Chu, H., Byrreddy, S. N., Spearman, P. & Chakraborty, R. Placental Hofbauer
718 cells assemble and sequester HIV-1 in tetraspanin-positive compartments that are accessible
719 to broadly neutralizing antibodies. *J. Int. AIDS Soc.* **18**, (2015).
- 720 92. Schwartz, D. A. *et al.* Hofbauer Cells and COVID-19 in PregnancyMolecular Pathology Analysis
721 of Villous Macrophages, Endothelial Cells, and Placental Findings From 22 Placentas Infected

- 722 by SARS-CoV-2 With and Without Fetal Transmission. *Arch. Pathol. Lab. Med.* **145**, 1328–1340
723 (2021).
- 724 93. Davidson, K. W. *et al.* Aspirin Use to Prevent Preeclampsia and Related Morbidity and
725 Mortality: US Preventive Services Task Force Recommendation Statement. *JAMA* **326**, 1186–
726 1191 (2021).
- 727 94. Henderson, J. T., Vesco, K. K., Senger, C. A., Thomas, R. G. & Redmond, N. Aspirin Use to
728 Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and
729 Systematic Review for the US Preventive Services Task Force. *JAMA* **326**, 1192–1206 (2021).
- 730 95. Ray, J. G., Abdulaziz, K. E., Berger, H. & DOH-NET (Diabetes, O. and H. in P. R. N. Aspirin Use
731 for Preeclampsia Prevention Among Women With Prepregnancy Diabetes, Obesity, and
732 Hypertension. *JAMA* **327**, 388–390 (2022).
- 733 96. Weckman, A. M., Ngai, M., Wright, J., McDonald, C. R. & Kain, K. C. The Impact of Infection in
734 Pregnancy on Placental Vascular Development and Adverse Birth Outcomes. *Front. Microbiol.*
735 **10**, (2019).
- 736 97. Stamatovic, S. M., Keep, R. F., Mostarica-Stojkovic, M. & Andjelkovic, A. V. CCL2 Regulates
737 Angiogenesis via Activation of Ets-1 Transcription Factor. *J. Immunol.* **177**, 2651–2661 (2006).
- 738 98. Salcedo, R. *et al.* Human endothelial cells express CCR2 and respond to MCP-1: direct role of
739 MCP-1 in angiogenesis and tumor progression. *Blood* **96**, 34–40 (2000).
- 740 99. Ferrari, A. Global, regional, and national burden of 12 mental disorders in 204 countries and
741 territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
742 *The Lancet Psychiatry* **9**, 137–150 (2022).
- 743 100. Seney, M. L., Glausier, J. & Sibille, E. Large-Scale Transcriptomics Studies Provide Insight Into
744 Sex Differences in Depression. *Biol. Psychiatry* **91**, 14–24 (2022).
- 745 101. Intapad, S., Ojeda, N. B., Dasinger, J. H. & Alexander, B. T. Sex differences in the
746 developmental origins of cardiovascular disease. *Physiology* **29**, 122–132 (2014).
- 747 102. Hagenaars, S. P. *et al.* Genetic comorbidity between major depression and cardio-metabolic
748 traits, stratified by age at onset of major depression. *Am. J. Med. Genet. Part B*
749 *Neuropsychiatr. Genet.* **183**, 309–330 (2020).
- 750 103. Oliva, M. *et al.* The impact of sex on gene expression across human tissues. *Science* **369**,
751 (2020).
- 752

753 **Figure captions**

754 Figure 1

755 **WGCNA of placental villous RNA sequencing data identifies a module of homeostatic inflammation**
756 **that is highly enriched in Hofbauer cells.** A) Heatmap of the topological overlap matrix, with
757 corresponding dendrogram and module assignment (represented as colours). B) Gene ontology
758 analysis of biological processes for the cyan module, ranked by $-\log$ of the adjusted p-value. Dashed
759 line indicates FDR threshold for multiple comparisons. C) The top panel shows the cyan module
760 score in scRNA-seq data from Vento-Tormo *et al.* The bottom panel shows expression of the
761 Hofbauer cell marker *FOLR2*. D) Forest plot of the PGS coefficient from multiple regression analyses
762 with 95% confidence intervals, estimating the effect of various PGS on single sample gene set
763 enrichment analysis scores from the cyan module of the GUSTO RNA-seq dataset. The first 3 genetic
764 principal components and sex were used as covariates in the analysis (n=42). E) Multiple regression
765 analysis investigating the effect of the fetoplacental PGS on 27 molecules measured in cord blood.
766 All outcomes were log transformed and scaled. The first 3 genetic principal components, sex and
767 gestational age at birth were used as covariates in the analyses (n=194-251).

768

769 Figure 2

770 **Phenome-wide association study and mendelian randomization analyses identify associations**
771 **between the placental homeostatic inflammation module and adult outcomes.** A) Manhattan plot
772 showing the $-\log$ p-value corresponding to the effect of the fetoplacental PGS on 1831 outcomes in
773 the full UK Biobank sample (males and females combined). Dashed line indicates the FDR threshold
774 for multiple comparisons, all values exceeding this threshold are labelled. Points are colored as per
775 their categorizations in the UK Biobank database. In each regression the first 10 genetic principal
776 components, age, sex, genotype array and assessment center (categorical variable) are used as
777 covariates. B) Logistic regression for the effect of the fetoplacental PGS on diagnoses in the UK
778 Biobank. The x-axis represents coefficient with 95% confidence intervals, green represents male and
779 female samples combined, yellow represents females only and blue represents males only. The first
780 40 genetic principal components, age, sex (only in combined sample), genotype array and
781 assessment center (categorical variable) were used as covariates in the analyses. The 5 outcomes
782 significantly associated with fetoplacental PGS after FDR correction in females are shown. C)
783 Mendelian randomization using the inverse variance weighted method is used to analyze the effect
784 of placental eQTLs on various outcomes. In both panels, green represents males and females
785 combined, yellow represents females only and blue represents males only. The x-axis represents the
786 IVW estimate with associated 95% confidence intervals. The first panel shows a significant effect for
787 coronary heart disease and myocardial infarction (p= 0.002 and 0.004, respectively), with no
788 significant association for MDD (p=0.09). The second panel illustrates the results from an analysis of
789 responses to the PHQ-9, which are stratified by sex. Concentration problems in men (p=0.017) and
790 suicidality in females (p=0.001) and the combined (p=0.003) were found to be significantly
791 associated with placental eQTLs, but only suicidality in females (FDR=0.014) and the combined
792 (FDR=0.028) samples retain significant association with placental eQTLs after correction for multiple
793 comparisons. Suicidality is highlighted in bold font to denote an FDR p-value < 0.05.

794 Figure 3

795 **The placental homeostatic inflammation module is highly enriched for genes differentially**
796 **regulated by intra-amniotic infection and preterm birth.** A) Enrichment analysis for genes

797 differentially expressed in the placenta under various conditions. Dashed line indicates threshold for
798 multiple comparisons. B) Drugs annotated in the Drug-Gene Interaction Database which target
799 members of the cyan module. Drug names are on the y-axis with the names of genes they target in
800 the cyan module labelled within their respective column. C) Average connectivity score of genes
801 differentially regulated by intra-amniotic infection, preterm birth or those found to be targets of
802 Aspirin. Dashed line indicates the mean connectivity of all cyan module genes.

803

804 Supplementary Figure 1

805 **WGCNA and cyan module PGS**. A) Outlier removal with hierarchical clustering of placental villous
806 samples prior to WGCNA. B) Cyan module network with nodes representing genes and color
807 representing connectivity score. C) Preservation analysis of WGCNA modules in Yang *et al*. Above the
808 dashed green line indicates strong evidence of preservation. D) Comparison of eQTLs used to
809 generate the fetoplacental PGS (y-axis) in all GTEx v8 tissues (along x-axis; last value is the placenta
810 eQTLs used in this study for comparison purposes). If an eQTL was identified in that tissue it is
811 colored with respect to its normalized effect size (NES) as indicated in the GTEx catalogue. E)
812 Correlation plot of the cyan module PGS and various perinatal factors. Empty box indicates no
813 significant correlation at an uncorrected p-value threshold of 0.05. Correlations with a p-value <0.05
814 have a color and size proportional to their r.

815

816 Supplementary Figure 2

817 **Cell type enrichment and transcription factor enrichment of the cyan module**. A) Enrichment of the
818 cyan module in scRNA-seq data from the Vento-Tormo *et al* (A) and Suryawanshi *et al* (B) both show
819 strong enrichment in Hofbauer cells. Note these studies also included maternal macrophages, which
820 are unlikely to be present in our dataset. C) Transcription factor enrichment analysis of the cyan
821 module using ChEA3 and the Top Rank analysis.

822

823 Supplementary Figure 3

824 **Correlation of fetoplacental PGS with major depression disorder (MDD) PRS and cardiovascular
825 disorder (CVD) PRS**. Empty box indicates no correlation at an uncorrected p-value threshold of 0.05.
826 Correlations with a p-value <0.05 have a color and size proportional to their r.

827

828 Supplementary Figure 4

829 **Logistic regression for female significant multiple regression diagnoses associations in the UK
830 Biobank using diagnosis and PRS covariates**. Across all panels the x-axis represents the coefficient
831 with 95% confidence intervals, yellow represents females only. The first 40 genetic principal
832 components, age, genotype chip and assessment center are used as covariates in all analyses. The
833 first panel displays the results of a logistic regression for depression in females when the covariates
834 on the y-axis were separately added to the model. The second panel displays the results of a logistic
835 regression for Chronic ischaemic heart disease in females when the covariates on the y-axis were
836 separately added to the model.

837

838 Supplementary Figure 5

839 **Scatterplot, single SNP and leave one out analysis for myocardial infarction.** A) Scatterplot of SNPs
840 with their effect size for cyan module gene expression (x-axis) and myocardial infarction (y-axis).
841 Dark blue line uses the weighted median method and the light blue line uses the IVW method. B)
842 Single SNP analysis for individual SNPs (in black using the Wald ratio) and combined analysis using
843 the IVW method (red). C) IVW results of the analysis when each SNP is sequentially removed from
844 the analysis. Removed SNP indicated on the y-axis, combined IVW for all SNPs is in red. IVW; Inverse
845 Variance Weighted.

846

847 Supplementary Figure 6

848 **Scatterplot, single SNP and leave one out analysis for coronary heart disease.** A) Scatterplot of
849 SNPs with their effect size for cyan module gene expression (x-axis) and coronary heart disease (y-
850 axis). Dark blue line uses the weighted median method and the light blue line uses the IVW method.
851 B) Single SNP analysis for individual SNPs (in black using the Wald ratio) and combined analysis using
852 the IVW method (red). C) IVW results of the analysis when each SNP is sequentially removed from
853 the analysis. Removed SNP indicated on the y-axis, combined IVW for all SNPs is in red. IVW; Inverse
854 Variance Weighted.

855

856 Supplementary Figure 7

857 **Scatterplot, single SNP and leave one out analysis for major depressive disorder.** A) Scatterplot of
858 SNPs with their effect size for cyan module gene expression (x-axis) and major depressive disorder
859 (y-axis). Dark blue line uses the weighted median method and the light blue line uses the IVW
860 method. B) Single SNP analysis for individual SNPs (in black using the Wald ratio) and combined
861 analysis using the IVW method (red). C) IVW results of the analysis when each SNP is sequentially
862 removed from the analysis. Removed SNP indicated on the y-axis, combined IVW for all SNPs is in
863 red. IVW; Inverse Variance Weighted.

864

865 Supplementary Figure 8

866 **Scatterplot, single SNP and leave one out analysis for suicidality (females only).** A) Scatterplot of
867 SNPs with their effect size for cyan module gene expression (x-axis) and suicidality (females only; y-
868 axis). Dark blue line uses the weighted median method and the light blue line uses the IVW method.
869 B) Single SNP analysis for individual SNPs (in black using the Wald ratio) and combined analysis using
870 the IVW method (red). C) IVW results of the analysis when each SNP is sequentially removed from
871 the analysis. Removed SNP indicated on the y-axis, combined IVW for all SNPs is in red. IVW; Inverse
872 Variance Weighted.

873

874 Supplementary Figure 9

875 **Scatterplot, single SNP and leave one out analysis for suicidality (males and females combined).** A)
876 Scatterplot of SNPs with their effect size for cyan module gene expression (x-axis) and suicidality
877 (males and females combines; y-axis). Dark blue line uses the weighted median method and the light
878 blue line uses the IVW method. B) Single SNP analysis for individual SNPs (in black using the Wald

879 ratio) and combined analysis using the IVW method (red). C) IVW results of the analysis when each
880 SNP is sequentially removed from the analysis. Removed SNP indicated on the y-axis, combined IVW
881 for all SNPs is in red. IVW; Inverse Variance Weighted.

882

883

884

Figure 1




Figure 2




Figure 3

